fusão NTRK em tumores de glândulas salivares — praticamente 100% de carcinoma analógico...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | BMA-NTRK-FUSION-SALIVARY |
|---|---|
| Tipo | Relevância terapêutica |
| Estado | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Doenças | DIS-SALIVARY |
| Fontes | SRC-FDA-CDS-2026 |
Fatos de ação
| Biomarcador | BIO-NTRK-FUSION |
|---|---|
| Variante | fusão NTRK1/2/3 (ETV6-NTRK3 define carcinoma analógico mamário secretor, MASC) |
| Doença | DIS-SALIVARY |
| Nível ESCAT | IA |
| Combinações recomendadas | larotrectinib monotherapy, entrectinib monotherapy (preferred for CNS disease) |
| Resumo das provas | NTRK fusion in salivary gland tumors — virtually 100% of mammary analogue secretory carcinoma (MASC) carry ETV6-NTRK3. Larotrectinib (NAVIGATE / pooled phase 1/2, Drilon NEJM 2018 — ORR 75% across tumor types, salivary subset ORR ~85%) and entrectinib (STARTRK-2 / ALKA / STARTRK-NG) are FDA-approved tumor-agnostic for NTRK-fusion solid tumors. Salivary MASC has among the highest response rates. |
Notas
ESCAT IA. OncoKB Level 1. MASC re-classified from acinic cell carcinoma in 2010 — driven entirely by ETV6-NTRK3 fusion. Detection: pan-TRK IHC screen → confirm by FISH or NGS. Resistance: solvent-front (NTRK G595R / G623R) and gatekeeper (G667C) mutations → next-gen TRK inhibitor selitrectinib / repotrectinib in trials. Source-gap: SRC-NCCN-HEAD-AND-NECK / SRC-NAVIGATE-DRILON-2018 / SRC-STARTRK2-DRILON-2020 not yet ingested.
Usado por
Não há referências reversas encontradas no corpus YAML.